Sarepta Therapeutics (SRPT) Says FDA Requests Dystrophin Data

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has requested that Sarepta provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory study of eteplirsen (PROMOVI), as part of its ongoing evaluation of the eteplirsen New Drug Application (NDA). The Company plans to submit data from thirteen patient biopsy samples, at baseline and Week 48, to the FDA over the coming weeks to facilitate a prompt decision on the NDA by the Agency.

You May Also Be Interested In

• MSG Rangers, Huron Consulting to join S&P SmallCap 600
• Sarepta preclinical data shows SRP-1003 reduces DM1 RNA in nucleus
• Trump On Iran: Making Up Fake Hits, Mines, And Everything Else To Drive Up Price Of Oil